Oral Rivaroxaban for Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring. METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study. RESULTS: The study of rivaroxaban for acute DVT included 3449 patients: 1731 given rivaroxaban and 1718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%], vs. 51 events with enoxaparin-vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P<0.001). The principal safety outcome occurred in 8.1% of the patients in each group. In the continued-treatment study, which included 602 patients in the rivaroxaban group and 594 in the placebo group, rivaroxaban had superior efficacy (8 events [1.3%], vs. 42 with placebo [7.1%]; hazard ratio, 0.18; 95% CI, 0.09 to 0.39; P<0.001). Four patients in the rivaroxaban group had nonfatal major bleeding (0.7%), versus none in the placebo group (P=0.11). CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. (Funded by Bayer Schering Pharma and Ortho-McNeil; ClinicalTrials.gov numbers, NCT00440193 and NCT00439725.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
Citations
Cites
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Turpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
In-Stent Restenosis in the Drug-Eluting Stent Era
Dangas, G. D., Claessen, B. E., Caixeta, A., Sanidas, E. A., Mintz, G. S., & Mehran, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.028 · Cited by 803
Incidence of Venous Thromboembolism: A Community-based Study in Western France
Oger, E., & the EPI-GETBO Study Group (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613887 · Cited by 711
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Rodger, M. A., Kahn, S. R., Wells, P. S., Anderson, D. A., Chagnon, I., Le Gal, G., Solymoss, S., Crowther, M., Perrier, A., White, R., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080493 · Cited by 581
Research works printed but not linked: 1
- Hutten BA, 2006, Cochrane Database Syst Rev, 1, CD001367
Cited by
Items 701–800 of 1,010
Dobrowolski, C., Clark, E. G., & Sood, M. M. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1437-1 · Cited by 33
Weitz, J. I., Jaffer, I., & Fredenburgh, J. C. (2017) · F1000Research · doi:10.12688/f1000research.11174.1 · Cited by 38
Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism
Moustafa, F., Giorgi‐Pierfranceschi, M., Micco, P. D., Bucherini, E., Lorenzo, A., Villalobos, A., Nieto, J. A., Valero, B., Samperiz, A. L., Monréal, M., et al. (2017) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12036 · Cited by 34
Direct oral anticoagulants: An update
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.07.005 · Cited by 34
Riess, H. B., Ay, C., Bauersachs, R. M., Becattini, C., Beyer‐Westendorf, J., Cajfinger, F., Chau, I., Cohen, A. T., Khorana, A. A., Maraveyas, A., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0473 · Cited by 33
Ageno, W., Mantovani, L. G., Haas, S. K., Kreutz, R. H., Monje, D., Schneider, J., Bugge, J., Gebel, M., & Turpie, A. G. G. (2019) · TH Open · doi:10.1055/s-0039-1683968 · Cited by 32
Kubo, K., Kato, M., Mabe, K., Harada, N., Iboshi, Y., Kagaya, T., Ono, M., Toyokawa, T., Yamashita, H., Kuwai, T., et al. (2019) · Digestion · doi:10.1159/000502952 · Cited by 31
Unanswered questions in cancer‐associated thrombosis
Sanfilippo, K. M., Moik, F., Candeloro, M., Ay, C., Nisio, M. D., & Lee, A. Y. Y. (2022) · British Journal of Haematology · doi:10.1111/bjh.18276 · Cited by 32
Noble, S., Nelson, A., Fitzmaurice, D. A., Bekkers, M., Baillie, J., Sivell, S., Canham, J. E., Smith, J. D., Casbard, A. C., Cohen, A. T., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19830 · Cited by 31
Prophylaxis and treatment of venous thromboembolism in the critically ill
Adriance, S. M., & Murphy, C. V. (2013) · International Journal of Critical Illness and Injury Science · doi:10.4103/2229-5151.114274 · Cited by 35
Onundarson, P. T., Francis, C. W., Indridason, Ó. S., Arnar, D. O., Bjornsson, E. S., Magnússon, M. K., Júlíusson, S., Jensdottir, H. M., Viðarsson, B., Gunnarsson, P., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00073-3 · Cited by 32
Elboudwarej, O., Patel, J. K., Liou, F., Rafiei, M., Osborne, A. D., Chai, W., Kittleson, M. M., Czer, L. S. C., Stern, L. K., Esmailian, F., et al. (2015) · Clinical Transplantation · doi:10.1111/ctr.12566 · Cited by 31
Bouée, S., Emery, C., Samson, A., Gourmelen, J., Bailly, C., & Cotté, F.-E. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0078-0 · Cited by 38
Shaw, J. R., de Wit, C., Gal, G. L., & Carrier, M. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13670 · Cited by 31
He, L., Kochan, J. P., Lin, M., Vandell, A. G., Brown, K. S., & Depasse, F. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.05.005 · Cited by 31
Zhang, L., Zhang, H., Zhang, J., Tian, H., Liang, J., & Liu, Z. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5471 · Cited by 33
Li, R., Yuan, M., Cheng, J., Yu, S., Wei, W., Fu, W., Prandoni, P., & Chen, Y. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.09.014 · Cited by 37
Sindet-Pedersen, C., Staerk, L., Pallisgaard, J. L., Gerds, T. A., Berger, J. S., Torp-Pedersen, C., Gislason, G. H., & Olesen, J. B. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy021 · Cited by 30
“5% in the AMPLIFY study.(8,9) Allcause mortality can be used as a measure of how the general health is of the investigated patient population.”
A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban
Kreutz, R. H. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-1029-2 · Cited by 32
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of the Literature
Maan, A., Padmanabhan, R., Shaikh, A. Y., Mansour, M., Ruskin, J. N., & Heist, E. K. (2012) · Cardiology in Review · doi:10.1097/crd.0b013e3182503e2d · Cited by 36
New anticoagulants: A concise review
Kreuziger, L. B., Morton, C. T., & Dries, D. J. (2012) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e318265cf9e · Cited by 31
Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia
Sartori, M., Favaretto, E., Cini, M., Legnani, C., & Cosmi, B. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1208-4 · Cited by 30
“Similarly to dabigatran, rivaroxaban does not show any interaction with PF4 [10], and a randomized controlled trial has established the efficacy of rivaroxaban, an oral in the treatment of venous thromboembolism, in the general population [4].”
BackgroundPreclinical and clinical data for factor Xa and “universal” reversal agents
Milling, T. J., & Kaatz, S. (2016) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2016.09.052 · Cited by 32
Barbui, T., Stefano, V. D., Falanga, A., Finazzi, G., Martinelli, I., Rodeghiero, F., Vannucchi, A. M., & Barosi, G. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0225-5 · Cited by 32
Heyard, R., Held, L., Schneeweiß, S., & Wang, S. V. (2024) · BMJ Medicine · doi:10.1136/bmjmed-2023-000709 · Cited by 34
Shaya, S. A., Saldanha, L. J., Vaezzadeh, N., Zhou, J., Ni, R., & Gross, P. L. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13182 · Cited by 31
Mao, L., Li, C., Li, T., & Yuan, K. (2013) · Vascular · doi:10.1177/1708538113490423 · Cited by 32
“It has been reported to prevent venous thromboembolism more effectively than enoxaparin in patients undergoing orthopedic surgery(18) and was non-inferior to enoxaparin followed by warfarin in a study involving patients with established venous thrombosis.(19) However, rare research of rivaroxaban on prevention of stro…”
BackgroundLoffredo, L., Violi, F., & Perri, L. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.086 · Cited by 31
Alzghari, S. K., Seago, S. E., Garza, J. E., Hashimie, Y., Baty, K. A., Evans, M. F., Shaver, C. N., & Herrington, J. D. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217718382 · Cited by 31
Age‐adjusted D‐dimer cutoff for the diagnosis of pulmonary embolism: A cost‐effectiveness analysis
Blondon, M., Gal, G. L., Meyer, G., Righini, M., & Robert‐Ebadi, H. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14733 · Cited by 31
Historical perspective and future direction of coagulation research
Saito, H., Matsushita, T., & Kojima, T. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04362.x · Cited by 35
Practical Considerations for Use of Direct Oral Anticoagulants in Children
Whitworth, H., & Raffini, L. J. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.860369 · Cited by 31
The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure
Flierl, U., Fraccarollo, D., Micka, J., Bauersachs, J. K., & Schäfer, A. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.05.002 · Cited by 32
Novel oral anticoagulants: What dermatologists need to know
Plovanich, M., & Mostaghimi, A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.11.013 · Cited by 30
Goto, M., Miura, S., Suematsu, Y., Idemoto, Y., Takata, K., Imaizumi, S., Uehara, Y., & Saku, K. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.212 · Cited by 29
Pignataro, B. S., Nishinari, K., Cavalcante, R. N., Centofanti, G., Yazbek, G., Krutman, M., Bomfim, G. A. Z., Fonseca, I. Y. I., Teivelis, M. P., Wolosker, N., et al. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616677800 · Cited by 32
Simmons, B. S., Wysokiński, W. E., Saadiq, R. A., Bott‐Kitslaar, D. M., Henkin, S., Casanegra, A. I., Lenz, C. J., Daniels, P. R., Bjarnason, H., Vargas, E. R., et al. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13074 · Cited by 30
The diagnosis and management of pulmonary embolism
Toplis, E., & Mortimore, G. (2020) · British Journal of Nursing · doi:10.12968/bjon.2020.29.1.22 · Cited by 31
Assessment of coronary artery disease during hospitalization for cancer treatment
Mrotzek, S. M., Lena, A., Hadzibegovic, S., Ludwig, R., Al‐Rashid, F., Mahabadi, A. A., Mincu, R. I., Michel, L., Johannsen, L., Hinrichs, L., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01719-5 · Cited by 35
Review on Characteristics and Analytical Methods of Rivaroxaban
Reçber, T., Haznedaroğlu, İ. C., & Çelebier, M. (2020) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2020.1839735 · Cited by 31
Nagler, M., Bachmann, L. M., Schmid, P., Müller, P. R., & Wuillemin, W. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095761 · Cited by 29
Wang, Y., Wang, C., Chen, Z., Zhang, J., Liu, Z., Jin, B., Ying, K., Liu, C., Shao, Y., Jing, Z., et al. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-25 · Cited by 30
Self-citationNational trends in hospitalizations for venous thromboembolism
Brahmandam, A., Abougergi, M. S., & Chaar, C. I. O. (2017) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2017.04.006 · Cited by 31
Kang, J. M., Park, K. H., Ahn, S., Cho, S., Han, A., Lee, T., Jung, I. M., Kim, J. Y., & Min, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-56887-w · Cited by 29
Alfirevic, A., Downing, J., Daras, K., Comerford, T., Pirmohamed, M., & Barr, B. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033357 · Cited by 30
Prevention of venous thromboembolism in ambulatory patients with cancer
Khorana, A. A., Cohen, A. T., Carrier, M., Meyer, G., Pabinger, I., Kavan, P., & Wells, P. S. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000948 · Cited by 32
Preblick, R., Kwong, W. J., White, R. H., & Goldhaber, S. Z. (2015) · Hospital Practice · doi:10.1080/21548331.2015.1099412 · Cited by 28
Diretriz de Avaliação Cardiovascular Perioperatória da Sociedade Brasileira de Cardiologia – 2024
Gualandro, D. M., Fornari, L. S., Caramelli, B., Abizaid, A., Gomes, B. R., Tavares, C. A. M., Fernandes, C. J. C. D. S., Polanczyk, C. A., Jardim, C., Vieira, C. L. Z., et al. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240590 · Cited by 43
Tripodi, A., & Palareti, G. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02541.x · Cited by 28
Practical aspects of the oral new anticoagulants
DeLoughery, T. G. (2011) · American Journal of Hematology · doi:10.1002/ajh.22021 · Cited by 29
Wells, P. S., Gebel, M., Prins, M. H., Davidson, B. L., & Lensing, A. W. A. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-26 · Cited by 29
Cove, C. L., & Hylek, E. M. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000136 · Cited by 32
A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism
Comerota, A. J., & Ramacciotti, E. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.03.018 · Cited by 29
Renlund, H., Svensson, P. J., Själander, A., & Sandén, P. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-06-0489 · Cited by 30
Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?
Rességuier, A.-S., Pereira, B., Rieu, V., Guenno, G. L., Grobost, V., & Ruivard, M. (2017) · Lupus · doi:10.1177/0961203317701841 · Cited by 28
Anticoagulation prescribing patterns in patients with cancer
Xiang, E., Ahuja, T., Raco, V., Cirrone, F., Green, D., & Papadopoulos, J. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1558-1 · Cited by 32
Iyer, R. S., Ramakrishnan, T. C. R., Akhtar, S., Muthukalathi, K., Kumar, P., & Muthukumar, K. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.10.015 · Cited by 28
Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
Song, A. B., Rosovsky, R. P. G., Connors, J. M., & Al-Samkari, H. T. (2019) · Vascular Health and Risk Management · doi:10.2147/vhrm.s132556 · Cited by 29
Extended anticoagulation after venous thromboembolism: should it be done?
Fernandes, C. J. C. D. S., Calderaro, D., Piloto, B. M., Hoette, S., Jardim, C., & Souza, R. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619878556 · Cited by 28
Rivaroxaban in patients with mechanical heart valves: A pilot study
Roost, E., Weber, A. C., Alberio, L., Englberger, L., Reineke, D., Keller, D., Nagler, M., & Carrel, T. P. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.12.005 · Cited by 28
Bixby, A. L., Shaikh, S. A., Naik, A. S., Cotiguala, L., McMurry, K. A., Samaniego, M., Marshall, V. D., & Park, J. M. (2020) · Transplant International · doi:10.1111/tri.13599 · Cited by 29
Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?
Weitz, J. I., Prandoni, P., & Verhamme, P. B. (2020) · TH Open · doi:10.1055/s-0040-1721735 · Cited by 35
Bertoletti, L., Gusto, G., Khachatryan, A., Quignot, N., Chaves, J., Moniot, A., & Mokgokong, R. (2022) · Thrombosis and Haemostasis · doi:10.1055/a-1731-3922 · Cited by 32
Jeong, I., Alotaibi, M., Fernandes, T. M., Kim, S., Kerr, K. M., Yang, J. Z., Pretorius, V. G., Madani, M. M., & Kim, N. H. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12110 · Cited by 28
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE
Turpie, A. G. G., Farjat, A. E., Haas, S. K., Ageno, W., Weitz, J. I., Goldhaber, S. Z., Goto, S., Angchaisuksiri, P., Kayani, G., Lópes, R. D., et al. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.11.016 · Cited by 28
Hosokawa, K., Abe, K., Funakoshi, K., Tamura, Y., Nakashima, N., Todaka, K., Taniguchi, Y., Inami, T., Adachi, S., Tsujino, I., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.03.036 · Cited by 30
Treatment with novel oral anticoagulants: indications, efficacy and risks
Ghanny, S., & Crowther, M. A. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328363c170 · Cited by 32
Palareti, G. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.02.002 · Cited by 29
Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach
Agnelli, G., & Becattini, C. (2015) · European Respiratory Journal · doi:10.1183/09031936.00164714 · Cited by 33
Assessment of Patient Adherence to Direct Oral Anticoagulant vs Warfarin Therapy
Patel, S. I., Cherington, C. C., Scherber, R. M., Barr, K., McLemore, R. Y., Morisky, D. E., Cha, S., Mookadam, F., & Shamoun, F. E. (2017) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2017.002 · Cited by 31
Huang, H., Lin, S., Cheng, S., & Wang, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-21884-y · Cited by 28
Aloi, K. G., Fierro, J. J., Stein, B. J., Lynch, S. M., & Shapiro, R. J. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019854578 · Cited by 28
The relationship between DOAC levels and clinical outcomes: The measures tell the tale
Toorop, M. M. A., Lijfering, W. M., & Scheres, L. J. J. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15104 · Cited by 32
Rivaroxaban for the treatment of cerebral venous thrombosis
Esmaeili, S., Abolmaali, M., Aarabi, S., Motamed, M. R., Chaibakhsh, S., Joghataei, M. T., Mojtahed, M., & Mirzaasgari, Z. (2021) · BMC Neurology · doi:10.1186/s12883-021-02091-1 · Cited by 30
Harel, Z., Sood, M. M., & Perl, J. M. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000098 · Cited by 29
de Jong, P. G., Coppens, M., & Middeldorp, S. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09196.x · Cited by 29
Ageno, W., Mantovani, L. G., Haas, S. K., Kreutz, R. H., Haupt, V., Schneider, J., & Turpie, A. G. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-16 · Cited by 29
Current State of Knowledge on Oral Anticoagulant Reversal Using Procoagulant Factors
Nitzki‐George, D., Wozniak, I., & Caprini, J. A. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r724 · Cited by 27
The new oral anticoagulants: Reasonable alternatives to warfarin
Roca, B., & Roca, M. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.14052 · Cited by 28
Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines
Kim, Y. H., Min, S., Kang, J. M., Kim, H.-K., Bae, J. I., Choi, S. Y., Park, S. J., Chang, J.-H., Park, U. J., Kim, C. W., et al. (2016) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2016.75.4.233 · Cited by 27
Singer, A. J., Quinn, A., Dasgupta, N., & Thode, H. C. (2016) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2016.09.028 · Cited by 33
Moustafa, F., Pesavento, R., Micco, P. D., González‐Martínez, J., Quintavalla, R., Peris, M. L., Porras, J. A., Falvo, N., Baños, P., Monréal, M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.781 · Cited by 30
Self-citationOnce- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation
Ageno, W., Beyer‐Westendorf, J., & Rubboli, A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1361405 · Cited by 29
Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series
Smetana, K. S., Dunne, J., Parrott, K., Davis, G. A., Collier, A. C. S., Covell, M. B., & Smyth, S. S. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1560-7 · Cited by 27
Lam, E., Bashir, B., Chaballa, M., & Kraft, W. K. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1637733 · Cited by 27
Cowie, M., Lamy, A. L., Lévy, P., Mealing, S., Millier, A., Mernagh, P., Cristeau, O., Bowrin, K., & Brière, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz278 · Cited by 30
Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions
Riva, N., & Ageno, W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030743 · Cited by 29
Rivaroxaban: Expanded Role in Cardiovascular Disease Management—A Literature Review
Ajmal, M., Friedman, J., Sipra, Q. U. A. R., & Lassar, T. A. (2021) · Cardiovascular Therapeutics · doi:10.1155/2021/8886210 · Cited by 34
The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations
Ashton, V., Kerolus‐Georgi, S., & Moore, K. T. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1838 · Cited by 34
Vlazny, D. T., Pasha, A. K., Kuczmik, W., Wysokiński, W. E., Bartlett, M. A., Houghton, D. E., Casanegra, A. I., Daniels, P. R., Froehling, D. A., White, L. J., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15416 · Cited by 30
Venous Thromboembolism and Pulmonary Embolism
Blitzer, R. R., & Eisenstein, S. G. (2021) · Surgical Clinics of North America · doi:10.1016/j.suc.2021.06.015 · Cited by 30
Lutsey, P. L., Walker, R. F., MacLehose, R. F., Norby, F. L., Evensen, L. H., Alonso, Á., & Zakai, N. A. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020428 · Cited by 31
The use of rivaroxaban for short- and long-term treatment of venous thromboembolism
Cohen, A. T., & Dobromirski, M. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-12-0859 · Cited by 28
Succinct Review of the New VTE Prevention and Management Guidelines
Pollak, A. W., & McBane, R. D. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.015 · Cited by 28
Kline, J. A., Jiménez, D., Courtney, D. M., Ianus, J., Cao, L., Lensing, A. W. A., Prins, M. H., & Wells, P. S. (2016) · Academic Emergency Medicine · doi:10.1111/acem.12865 · Cited by 27
Margolis, J. M., Deitelzweig, S. B., Kline, J. A., Tran, O., Smith, D. M., Bookhart, B., Crivera, C., & Schein, J. R. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003788 · Cited by 27
van Es, N., Wells, P. S., & Carrier, M. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.02.016 · Cited by 32
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
Coleman, C. I., Beyer‐Westendorf, J., Bunz, T. J., Mahan, C. E., & Spyropoulos, A. C. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618758955 · Cited by 29
Fifty years of research on antithrombotic therapy: Achievements and disappointments
Hirsh, J., Eikelboom, J. W., & Chan, N. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.10.023 · Cited by 29
Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio
Bernier, M., Lancrerot, S.-L., Parassol, N., Lavrut, T., Viotti, J., Rocher, F., & Drici, M. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000870 · Cited by 29
Metadata
- Authors
- The EINSTEIN Investigators
- Corresponding author
- The EINSTEIN Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2499-2510
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115787552
- Cited by
- 3,237
- References
- 19
- Citations by year
- 2026: 90 · 2025: 105 · 2024: 118 · 2023: 153 · 2022: 169 · 2021: 189 · 2020: 261 · 2019: 242 · 2018: 248 · 2017: 232 · 2016: 300 · 2015: 267 · 2014: 290 · 2013: 255 · 2012: 188
- FWCI
- 148.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- ORBi (University of Liège) (acceptedVersion, other-oa)
- Murdoch University Research Portal (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, oral factor Xa inhibitors, venous thromboembolism, deep vein thrombosis, continuation treatment, recurrent venous thromboembolism, enoxaparin, vitamin K antagonists, warfarin, acenocoumarol, major bleeding, non-inferiority
- MeSH terms
- Rivaroxaban, Acenocoumarol, Acute Disease, Administration, Oral, Aged, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Vitamin K, Warfarin, Enoxaparin, Venous Thrombosis, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.